NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) shares gapped up before the market opened on Tuesday . The stock had previously closed at $0.51, but opened at $0.62. NovaBay Pharmaceuticals shares last traded at $0.62, with a volume of 14,184 shares traded.

NBY has been the topic of a number of recent research reports. LADENBURG THALM/SH SH began coverage on shares of NovaBay Pharmaceuticals in a report on Wednesday, September 18th. They issued a “buy” rating and a $1.10 target price on the stock. Zacks Investment Research raised NovaBay Pharmaceuticals from a “hold” rating to a “buy” rating and set a $0.75 target price for the company in a report on Wednesday, November 20th.

The company has a 50-day moving average price of $0.68 and a 200-day moving average price of $1.02.

An institutional investor recently raised its position in NovaBay Pharmaceuticals stock. Renaissance Technologies LLC lifted its holdings in shares of NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) by 1,283.0% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 412,469 shares of the biopharmaceutical company’s stock after purchasing an additional 382,645 shares during the period. Renaissance Technologies LLC owned 1.96% of NovaBay Pharmaceuticals worth $697,000 at the end of the most recent reporting period.

NovaBay Pharmaceuticals Company Profile (NYSEAMERICAN:NBY)

NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets non-antibiotic and anti-infective products for the eye care market in the United States, China, and internationally. It offers Avenova, a prescription product for cleansing and removing foreign materials, including microorganisms and debris from skin around the eye; NeutroPhase for wound care market; CelleRx for the aesthetic dermatology market; Aganocide compounds patented synthetic molecules for use against bacteria, viruses, and fungi; auriclosene irrigation solution for urology; and intelli-Case, a device for soft and rigid gas permeable contact lenses.

See Also: Find a Trading Strategy That Works

Receive News & Ratings for NovaBay Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovaBay Pharmaceuticals and related companies with's FREE daily email newsletter.